secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001753926-25-001055
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 2.01, 2.03, 3.02, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics closes merger with LNHC, raises $50.1M PIPE
----------------------------------------------------------------

- Closed merger with LNHC (Ligand subsidiary) on July 1, 2025; LNHC shareholders own ~55.8% on fully diluted basis.
- Raised ~$50.1M in PIPE financing via Series A Preferred Stock at $1,000/share; Ligand participated.
- Effected 1-for-10 reverse stock split and changed name to Pelthos Therapeutics; ticker changes to PTHS on NYSE American.
- Appointed Scott Plesha as CEO/President; Francis Knuettel remains CFO; added four new directors to board.
- Entered royalty sale agreements for ZELSUVMI and other products with Nomis, Ligand, and Madison.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001055/0001753926-25-001055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001055/g084856_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer